Related Experiment Videos
The dominant negative effect of thyroid hormone receptor splicing variant alpha 2 does not require binding to a
R T Liu1, S Suzuki, T Miyamoto
1Department of Medicine, University of Chicago, Illinois 60637, USA.
Molecular Endocrinology (Baltimore, Md.)
|January 1, 1995
Summary
The thyroid hormone receptor variant-alpha 2 (TRv alpha 2) inhibits gene activation via a dominant negative effect. This occurs without binding to DNA, suggesting novel mechanisms involving transcription factors.
Area of Science:
- Molecular Biology
- Endocrinology
- Genetics
Background:
- Thyroid hormone receptors (TRs) regulate gene expression.
- TR variant-alpha 2 (TRv alpha 2) is a functionally inactive splice variant.
- TRv alpha 2 exhibits a dominant negative effect (DNE) on TR alpha 1 and TR beta 1 activity.
Purpose of the Study:
- Investigate the mechanisms underlying TRv alpha 2's dominant negative effect.
- Determine if DNA binding is required for TRv alpha 2's DNE.
- Explore alternative mechanisms for TRv alpha 2 mediated gene regulation.
Main Methods:
- Site-directed mutagenesis to create a DNA-binding domain (DBD) mutant of TRv alpha 2.
- Transient cotransfection assays with reporter genes.
- Gel shift assays to analyze receptor-DNA binding.
- Retinoid X receptor-alpha cotransfection experiments.
Main Results:
- A TRv alpha 2 mutant lacking DNA-binding capacity retained its dominant negative effect.
- TRv alpha 2 and its DBD mutant did not interfere with TR alpha 1 binding to thyroid hormone response elements (TREs).
- TRv alpha 2 inhibited constitutive transactivation independently of TRE binding.
Conclusions:
- The dominant negative effect of TRv alpha 2 does not require binding to thyroid hormone response elements.
- TRv alpha 2 may exert its dominant negative effect through interaction with basal transcription factors or other unrecognized pathways.
- Further research is needed to elucidate the precise molecular mechanisms of TRv alpha 2's inhibitory function.